Increasing Influenza and Tdap Vaccination of Pregnant Women

Overview

Pregnant women who get influenza are more likely than non-pregnant women to have serious complications, including hospitalizations, death, preterm labor and premature birth. Pertussis can cause hospitalization or death for newborns. However, influenza and Tdap vaccination rates for pregnant women are low nationally. In this study, the investigators will perform a randomized controlled trial aimed at practice change in obstetricians' offices, with an overall goal of reducing morbidity and mortality from influenza and pertussis infections.

Full Title of Study: “The VAX-MOM Study: Increasing Influenza and Tdap Vaccination of Pregnant Women”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Health Services Research
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 30, 2024

Detailed Description

Infants under 6 months of age at increased risk of both influenza (flu) and pertussis disease, and pregnant women risk serious illness and premature labor from flu. The Advisory Committee on Immunization Practices recommends that women receive a flu vaccine in flu season, and tetanus toxoid, reduced diphtheria toxoid, acellular pertussis (Tdap) vaccine during each pregnancy (ideally between 27-36 weeks) to lower the risk for flu and pertussis disease for themselves and their infants. However, only half of pregnant women in the US receive a flu and Tdap vaccine, respectively; only 33% of women receive both vaccines. Lack of vaccination stems from a combination of patient (lack of knowledge, vaccine hesitancy), provider (suboptimal communication skills, missed opportunities), and system (e.g. lack of standing orders and patient reminders) factors. An effective intervention is needed to improve flu and Tdap vaccination rates for pregnant women. To address these low vaccination rates the investigators plan to use a clustered RCT (randomizing practices), allocating half of the participating practice sites within each health system to the VAX-MOM intervention and the other half to standard of care. The multi-component VAX-MOM intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.

Interventions

  • Behavioral: VAX-MOM Intervention
    • The multi-component VAX-MOM intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.
  • Behavioral: Standard of Care
    • Standard vaccine education and processes provided to patients by obstetric practices.

Arms, Groups and Cohorts

  • Experimental: VAX-MOM Intervention
  • Active Comparator: Standard of Care

Clinical Trial Outcome Measures

Primary Measures

  • Change in the rate of influenza vaccination
    • Time Frame: 6 months during the 2019-2020 flu season (baseline), compared to 6 months during the 2021-2022 flu season (intervention)
    • Average rate of vaccination over 6 months during baseline will be compared with average rate of vaccination over 6 months during intervention, for vaccine eligible patients at participating OB/GYN practice sites. Vaccination status will be obtained from patient electronic health records.
  • Change in the rate of Tdap vaccination
    • Time Frame: 12 month baseline compared to 12 month intervention
    • Average rate of vaccination over 12 months during baseline will be compared with average rate of vaccination over 12 months during intervention, for vaccine eligible patients at participating OB/GYN practice sites. Vaccination status will be obtained from patient electronic health records.

Secondary Measures

  • Number of patients seen in the practices
    • Time Frame: 12 months during intervention period
  • Number of providers/nurses/staff completing training modules
    • Time Frame: 12 months during intervention period
  • Flu and Tdap vaccination rates by insurance group (public vs private)
    • Time Frame: 12 months during intervention period

Participating in This Clinical Trial

Inclusion Criteria

Patients

  • Sex is female – Pregnant – identified as being eligible for influenza or Tdap vaccine Providers – any provider, nurse or staff associated with the participating sites Exclusion Criteria:

Patients

  • none Providers – none

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Rochester
  • Collaborator
    • Centers for Disease Control and Prevention
  • Provider of Information About this Clinical Study
    • Principal Investigator: Cynthia Rand, Associate Professor – University of Rochester

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.